Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study. (EPITAX)

Regional University Hospital Center (CHRU)

Status: Completed

Conditions: Advanced Small Cell Lung Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT06550518

29BRC21.0086 - EPITAX

Details and patient eligibility

About

Initial chemosensitivity is known concerning SCLC but relapse is almost systematic, especially at a metastatic stage. Brain metastasis are identified around 40 to 50% during the evolution of the disease. Concerning the efficacy of epirubicin combined with paclitaxel from the second-line treatment, data is lacking more particularly about specific response on brain metastasis.

In this retrospective multicentric observational study in real life conditions, we try to evaluate systemic and specific cerebral efficacy and safety of a regimen combining epirubicin and paclitaxel in patients treated between 2010 and 2020 for a small cell lung carcinoma from the second-line treatment.

Enrollment: 29 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults (age ≥18 years)
• Histologically or cytologically SCLC diagnosis
• Treated with epirubicin-paclitaxel doublet between January 2010 and December 2020

Exclusion criteria

• Opposition to participate registered
• Patients under legal protection
• Patients afflicted by another subtype of lung carcinomas
• SCLC not treated with the epirubicin-paclitaxel doublet